'Clinical trials in Alzheimer's disease': immunotherapy approaches (Q27008979)

Pierre Jean Ousset

series ordinal

2

1 reference

Céline Caillaud

series ordinal

3

1 reference

language of work or name

1 reference

January 2012

1 reference

Journal of Neurochemistry

published in

1 reference

volume

120 Suppl 1

1 reference

page(s)

186-93

1 reference

Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Biomarkers in Alzheimer's disease: not yet surrogate endpoints.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Managing cognitive dysfunction through the continuum of Alzheimer's disease: role of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Intravenous Immunoglobulins as a Treatment for Alzheimerʼs Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Immunotherapy reduces vascular amyloid-beta in PDAPP mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X

Evaluation of the safety and immunogenicity of synthetic A 42 (AN1792) in patients with AD

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1471-4159.2011.07458.X